Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, ten have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $28.5455.

A number of research firms recently issued reports on ELAN. Leerink Partners upped their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. KeyCorp upped their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Finally, JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th.

Insiders Place Their Bets

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 4,971 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The shares were purchased at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Elanco Animal Health by 1.6% during the third quarter. Vanguard Group Inc. now owns 48,586,708 shares of the company’s stock valued at $978,536,000 after acquiring an additional 759,623 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after acquiring an additional 3,717,404 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Elanco Animal Health by 1.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after acquiring an additional 373,869 shares during the last quarter. UBS Group AG increased its position in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after acquiring an additional 5,961,457 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Elanco Animal Health by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after acquiring an additional 640,098 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN stock opened at $23.21 on Friday. Elanco Animal Health has a one year low of $13.23 and a one year high of $27.72. The company’s fifty day moving average price is $23.01 and its 200-day moving average price is $23.52. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a market capitalization of $11.59 billion, a PE ratio of -46.42, a price-to-earnings-growth ratio of 1.57 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the firm earned $0.37 earnings per share. The company’s quarterly revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities analysts anticipate that Elanco Animal Health will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.